BDBM305105 2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy-2- methylpropoxy)pyrazolo [1,5-a]pyridin-4-yl) pyridin-2-yl)-4- methylpiperidin-4-yl)- 2-methylpropanamide 2,2,2-trifluoroacetate::US10144734, Example 121::US10172845, Example 121::US10441581, Example 121::US10881652, Example 121::US11648243, Example 121

SMILES CC(C)(O)COc1cc(-c2ccc(nc2)N2CCC(C)(CC2)NC(=O)C(C)(C)c2ccc(Cl)cc2)c2c(cnn2c1)C#N

InChI Key InChIKey=JOTSHAHFXXVIPY-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 305105   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 276nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 1.62E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 276nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 1.62E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 276nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 1.62E+3nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 276nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 1.62E+3nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/1/2021
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 276nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent

LigandPNGBDBM305105(2-(4-chlorophenyl)- N-(1-(5-(3-cyano-6-(2- hydroxy...)
Affinity DataIC50: 1.62E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2023
Entry Details
US Patent